Once-Daily Pill Cuts Body Weight 11% in Major Obesity Trial
Orforglipron, an oral GLP-1 receptor agonist pill, delivered up to 11.2% weight loss over 72 weeks in a large phase 3 trial.
Riepilogo
The ATTAIN-1 phase 3 trial tested orforglipron, a first-of-its-kind oral small-molecule GLP-1 receptor agonist, in 3,127 adults with obesity over 72 weeks. Unlike injectable GLP-1 drugs such as semaglutide, orforglipron is a daily pill requiring no refrigeration or injections. The highest dose (36 mg) produced an average 11.2% body weight reduction versus 2.1% with placebo. Over half of patients on the top dose lost at least 10% of body weight. Improvements were also seen in waist circumference, blood pressure, triglycerides, and cholesterol. Side effects were mainly mild-to-moderate gastrointestinal symptoms, consistent with the GLP-1 drug class. Funded by Eli Lilly, this trial positions orforglipron as a potentially accessible oral alternative to injectable obesity therapies.
Riepilogo Dettagliato
GLP-1 receptor agonists have transformed obesity treatment, but their injectable delivery creates barriers for many patients. Orforglipron is a nonpeptide, small-molecule GLP-1 receptor agonist taken once daily as a pill — a design that could dramatically expand access to effective obesity pharmacotherapy.
The ATTAIN-1 trial enrolled 3,127 adults with obesity but without diabetes across multiple countries. Participants were randomized to once-daily orforglipron at 6 mg, 12 mg, or 36 mg, or placebo, as an adjunct to diet and physical activity guidance for 72 weeks. The primary endpoint was percent change in body weight at week 72.
All three doses significantly outperformed placebo. The 36 mg dose achieved a mean weight loss of 11.2%, compared to just 2.1% for placebo. Notably, 54.6% of patients on 36 mg lost ≥10% of body weight, and 18.4% lost ≥20%. Cardiometabolic markers also improved, including waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol — outcomes particularly relevant to longevity and cardiovascular risk reduction.
Adverse events were predominantly gastrointestinal — nausea, vomiting, diarrhea — consistent with the GLP-1 class profile. Discontinuation rates due to adverse events ranged from 5.3% to 10.3% across orforglipron groups versus 2.7% for placebo, indicating tolerability is meaningful but manageable.
The implications are significant. An effective oral GLP-1 agent without the cold-chain storage and injection requirements of semaglutide or tirzepatide could reach millions of patients currently unwilling or unable to use injectable therapies. However, the 11% weight loss at the top dose remains modestly below what leading injectables achieve, and longer-term cardiovascular outcome data are still needed.
Risultati Principali
- Orforglipron 36 mg produced 11.2% mean body weight reduction vs. 2.1% for placebo over 72 weeks.
- 54.6% of patients on 36 mg lost ≥10% body weight; 18.4% lost ≥20%.
- Waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol all significantly improved.
- Adverse events were mainly mild-to-moderate GI effects; discontinuation rates were 5.3–10.3%.
- As a once-daily oral pill, orforglipron eliminates injection and refrigeration barriers of current GLP-1 drugs.
Metodologia
Phase 3, multinational, randomized, double-blind, placebo-controlled trial (ATTAIN-1) with 3,127 adults with obesity and no diabetes. Participants received once-daily orforglipron (6 mg, 12 mg, or 36 mg) or placebo for 72 weeks in a 3:3:3:4 ratio. Primary endpoint was percent change in body weight at week 72 using an intention-to-treat treatment-regimen estimand.
Limitazioni dello Studio
Weight loss at the top dose (11.2%) is clinically meaningful but falls short of outcomes reported with injectable semaglutide or tirzepatide. The trial excluded patients with type 2 diabetes, limiting generalizability to a common obesity comorbidity. Long-term cardiovascular outcome data and post-marketing safety surveillance are still needed.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: